President Donald Trump signed an executive order directing federal regulators to accelerate the review of psychedelic drugs for treating post-traumatic stress disorder and traumatic brain injuries in military veterans. Trump stated the reforms aim to “dramatically accelerate access to new medical research and treatments based on psychedelic drugs,” emphasizing that experimental treatments “have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans.”
Trump highlighted the suicide crisis among veterans, stating that 21 times more veterans have died due to suicide compared to combat duty since 9/11, describing it as “a national tragedy.” He cited a 2024 Stanford University study involving 30 special operations veterans with traumatic brain injuries who underwent ibogaine treatment and experienced an 80% to 90% reduction in symptoms of depression and anxiety within one month.
The executive order directs the FDA to prioritize and fast-track applications for treatments showing early promise for PTSD, traumatic brain injury, depression, anxiety, and other mental health conditions. The order aims to utilize the FDA’s “breakthrough therapy” designation to shorten the timeline for reaching patients. Ibogaine and other psychedelics remain classified under the federal government’s most restrictive category for illegal, high-risk drugs.
The signing ceremony included podcaster Joe Rogan and Marcus Luttrell, a former Navy SEAL whose memoir formed the basis of the film “Lone Survivor.” Rogan stated Trump responded to his text about fast-tracking psychedelic research with “sounds great. Do you want FDA approval? Let’s do it.” Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, noted that ibogaine has proven “incredibly difficult to study in the U.S. because of its known cardiotoxicity.” He added that if the order enables objective scientific research, it “would help us understand whether it is truly a better psychedelic therapy than others.”
Critics cautioned that accelerating approval could raise safety and oversight concerns. No psychedelic has been approved in the U.S., though psilocybin, MDMA, and LSD are being studied in large trials for various mental health conditions.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://kutv.com/news/nation-world/trump-signs-order-to-speed-fda-review-of-psychedelic-drugs-citing-veterans-ptsd-post-traumatic-stress-disorder-depression-death-by-suicide-mental-health-treatments-therapy-mdma-psilocybin-clinical-trial-united-states-military-medication